Influenza B Burden in Latin America and Potential Benefits of the New Quadrivalent Vaccines

Arlant, Luiza Helena Falleiros; Bricks, Lúcia Ferro

doi:10.1093/jpids/piv107

Cited by 5 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, 2 studies, Barros et al 7 . and Arlant and Bricks, 55 summarized evidence corroborating our data collection on the circulation of B lineage. Our study is thus the first one to provide quantitative estimates of the benefits of vaccination with QIV instead of TIV.…”

Section: Discussionsupporting

confidence: 88%

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Jamotte

Clay

Macabéo

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin American countries. However, the circulation of 2 B lineages (Victoria and Yamagata) and difficulties in predicting the predominating lineage have led to the development of quadrivalent influenza vaccines (QIV), including both B lineages. Thus, the objective was to estimate the public health impact and influenza-related costs if QIV would have been used instead of TIV in 3 Latin American countries. We used a static model over the seasons 2010–2014 in Brazil, 2007–2014 in Colombia and 2006–2014 in Panama, focusing on population groups targeted by local vaccination recommendations: young children, adults with risk factors and the elderly. In Brazil, between 2010 and 2014, using QIV instead of TIV would have avoided US$ 6,200 per 100,000 person-years in societal costs, based on 168 influenza cases, 89 consultations, 3.2 hospitalizations and 0.38 deaths per 100,000 person-years. In Colombia and Panama, these would have ranged from US$ 1,000 to 12,700 (based on 34 cases, 13–25 consultations, 0.6–8.9 hospitalizations and 0.04–1.74 deaths) and from US$ 3,000 to 33,700 (based on 113 cases, 55–82 consultations, 0.5–27.8 hospitalizations and 0.08–6.87 deaths) per 100,000 person-years, respectively. Overall, the broader protection offered by QIV would have reduced the influenza humanistic and economic burden in the 3 countries. Despite the lack of local data leading to several extrapolations, this study is the first to give quantitative estimates of the potential benefits of QIV in Latin America.

show abstract

Section: Discussionsupporting

confidence: 88%

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Jamotte

Clay

Macabéo

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…A vacinação contra a influenza foi incluída no Calendário Nacional de Vacinação em 1999 e constitui a principal ação indicada para proteção contra a doença e suas potenciais complicações, principalmente as pneumonias, decorrentes da infecção pelo próprio vírus ou por infecção bacteriana secundária (4) . anterior (5) .…”

Section: Introductionunclassified

Análise Da Situação Vacinal Contra O Vírus Da Influenza Entre Professores: Estudo Transversal

Rabelo

Pereira

Alves

et al. 2023

Rev. Enferm. Atual In Derme

View full text Add to dashboard Cite

Objetivo: Analisar a situação vacinal contra o vírus da influenza entre professores do ensino básico. Método: Estudo transversal, utilizando-se questionário de elaboração própria respondido por 137 professores vinculados a 11 escolas de um município da Região Metropolitana de Fortaleza, Ceará, Brasil. A coleta ocorreu em setembro e outubro de 2019. Os dados foram analisados no Statistical Package for the Social Sciences versão 20.0. A análise estatística utilizou o teste qui-quadrado e razão de verossimilhança com intervalo de confiança de 95%. Resultados: A maioria dos professores foi vacinada (101; 73,7%), contudo, a meta vacinal de 90% não foi alcançada. Dificuldades relacionadas ao horário de funcionamento das unidades de saúde (14; 60,8%), falta de vacinas (9; 39,1%) e necessidade de comprovação profissional (6; 26,0%) foram relatadas. Predominou a vacinação em equipamentos de saúde próximos ao domicílio (49; 48,5%). Evidenciou-se reação adversa pós-vacinal (59; 58,4%), sendo mais frequente a dor local (50; 84,7%). Verificou-se em 2018 maior adesão à vacinação (107; 78,1%) em comparação aos anos de 2017 (88; 64,2%) e 2019 (101; 73,7%). Foram associados positivamente à decisão pela vacinação: faixa etária de 18 a 39 anos (p=0,021), filhos (p=0,046) e modalidade de ensino (p=0,016). Conclusão: A maioria dos professores foi vacinada, entretanto, em nenhum dos 3 anos estudados houve alcance da cobertura vacinal preconizada. A adesão oscilou no período, o que requer de gestores e profissionais de saúde planejamento e adequação de estratégias para o alcance de metas.

show abstract

“…However, from an epidemiological point of view, influenza A virus is of public concern due to its ability to rearrange genes with different species of birds and animals, generating potential pandemic strains; in contrast, human species is the host of IBV making the rearrangements of genes with different species unfeasible. Although global surveillance shows that influenza B viruses are responsible for approximately 20–25 % of infections during annual influenza seasons, in some seasons, they represent more than 50 % of infections, contributing to the overall mortality and morbidity, mainly in children <5 years old [21] , [22] , [23] , [24] . Considering the evolutionary pattern of influenza B viruses, our study aims to provide information regarding influenza B lineages circulating in different regions of Brazil, using RT-qPCR, instead of the hemagglutination inhibition assay, for the rapid identification of both antigenically and phylogenetically distinct influenza B viruses to obtain the benefits of quadrivalent vaccines.…”

Section: Introductionmentioning

confidence: 99%

Differentiation of influenza B lineages circulating in different regions of Brazil, 2014–2016, using molecular assay

et al. 2022

View full text Add to dashboard Cite

Influenza B Burden in Latin America and Potential Benefits of the New Quadrivalent Vaccines

Cited by 5 publications

References 8 publications

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Análise Da Situação Vacinal Contra O Vírus Da Influenza Entre Professores: Estudo Transversal

Differentiation of influenza B lineages circulating in different regions of Brazil, 2014–2016, using molecular assay

Contact Info

Product

Resources

About